Cardiovascular and kidney disease are the two most common conditions present at the same time in people living with type 2 diabetes. Data on the prevalence, quality of care and outcomes of people with these inter-related conditions is not available globally.
The iCaReMe Registry aims to address this unmet need. Developed by AstraZeneca in partnership with an independent external scientific committee, iCaReMe is a real-world evidence-based international observational study that is collecting data on cardio-renal complications in people with type 2 diabetes in routine clinical settings.
iCaReMe aims to:
Describe the characteristics of people with type 2 diabetes, heart failure and/or chronic kidney disease from clinical practices across multiple care settings and geographic regions – including those currently with limited availability of real world data.
Evaluate quality of care, including management of risk factors and use of guideline directed therapies.
Track long-term outcomes, including incidence of complications.
Inform future multidisciplinary interventions with the overarching goal of improving quality of care and outcomes on a global scale.
iCaReMe provides an in-depth cloud-based registry for healthcare professionals to follow up on their patients with diabetes and cardio-renal complications. Patient data (prospective or retrospective) is uploaded to a cloud-based registry. Criteria for patient inclusion includes:
Being over 18 years old.
Having type 2 diabetes, heart failure and/or chronic kidney disease
Providing written informed consent to participate in the study.
IDF supports the iCaReMe Registry and will work with AstraZeneca to:
Promote participation in the registry of healthcare professionals in low- and middle-income countries.
Raise awareness of the risk and potential consequences of cardio-renal complications in people living with diabetes.
Raise awareness on the socio-economic impact of cardio-renal complications in type 2 diabetes.
Advocate for policies to improve the prevention, detection and management of type 2 diabetes.
Enhance education of healthcare professionals on the importance of early diagnosis of cardio-renal complications in type 2 diabetes and the need to take appropriate action.